CLINICAL_TRIALS trial_result · 2025-06-13

Clinical Trial Update: Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease [Phase 3]

Phase 3 pediatric study evaluating GBT440 (voxelotor) on transcranial Doppler in sickle cell disease was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Pfizer | Conditions: Sickle Cell Disease | Phase 3 | Status: TERMINATED | Results posted: 2025-06-13